Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V540B in Healthy Adults
NCT06623409Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V540B in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE) at 6 months, Number of Participants Who Experience a Solicited Systemic AE at 6 months and 5 more. Started Nov 2024; status: recruiting.
02
Drugs
V540B
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06623409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623409.